Ignite Creation Date:
2024-05-06 @ 4:30 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05002595
Status:
COMPLETED
Last Update Posted:
2022-02-24
First Post:
2021-08-04
Brief Title:
H Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
Sponsor:
Soonchunhyang University Hospital
Organization:
Soonchunhyang University Hospital
Study Overview
Official Title:
Comparison of Helicobacter Pylori Treatment Between Modified Quadruple Therapy and Tailored Eradication Based on the Presence of Clarithromycin Resistance
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The rate of H pylori resistance to antimicrobial agents including clarithromycin CAM has increased worldwide Eradication failure using triple therapy is strongly associated with CAM-resistant H pylori The tailored therapy is defined as a targeted H pylori eradication which emphasizes on predicting individual drug responses before treatment
Dual priming oligonucleotide DPO-based multiplex polymerase chain reaction PCR was developed to diagnose H pylori infection and identify CAM resistance The use of DPO-PCR has increased the tailored H pylori eradication rate in Korea If DPO-PCR testing is not available a 14-day modified bismuth-containing quadruple regimen is recommended as a first-line H pylori eradication However there is no comparison study between modified quadruple therapy and tailored eradication based on the presence of CAM resistance using DPO-PCR
Dual priming oligonucleotide DPO-based multiplex polymerase chain reaction PCR was developed to diagnose H pylori infection and identify CAM resistance The use of DPO-PCR has increased the tailored H pylori eradication rate in Korea If DPO-PCR testing is not available a 14-day modified bismuth-containing quadruple regimen is recommended as a first-line H pylori eradication However there is no comparison study between modified quadruple therapy and tailored eradication based on the presence of CAM resistance using DPO-PCR
Detailed Description:
The investigators aim to evaluate the success rate adverse drug events and cost-effectiveness of modified quadruple therapy compared with tailored eradication based on the presence of CAM resistance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None